Skip to content
Screener

Crinetics Pharmaceuticals CRNX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$463.5M-6.0%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$9.42M+42.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.66M+84.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$36.85M-4.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$0-100%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$515K+214%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Year ending December 31,Minimum Payments
20297,425
20307,648
Thereafter35,903
Total future minimum lease payments70,284
Less imputed interest(22,429)
Total operating lease liabilities47,855
Less operating lease liabilities, current(6,536)
Operating lease liabilities, non-current$41,319

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's operating lease liabilities (total)?
Crinetics Pharmaceuticals (CRNX) reported operating lease liabilities (total) of $47.86M in Q1 2026.
How has Crinetics Pharmaceuticals's operating lease liabilities (total) changed year-over-year?
Crinetics Pharmaceuticals's operating lease liabilities (total) decreased by 5.8% year-over-year, from $50.82M to $47.86M.
What is the long-term trend for Crinetics Pharmaceuticals's operating lease liabilities (total)?
Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's operating lease liabilities (total) has grown at a 58.5% compound annual growth rate (CAGR), from $4.85M to $48.54M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Crinetics Pharmaceuticals's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude